Last update 03 Apr 2025

Izokibep

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
ABY 035, ABY-035, ABY-035/AFO2
+ [4]
Action
inhibitors, modulators
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors), albumin modulators(Serum albumin modulators)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hidradenitis SuppurativaPhase 3
United States
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Japan
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Canada
22 Jun 2023
Hidradenitis SuppurativaPhase 3
France
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Germany
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Hungary
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Poland
22 Jun 2023
Hidradenitis SuppurativaPhase 3
Spain
22 Jun 2023
Arthritis, PsoriaticPhase 3
United States
21 Nov 2022
Arthritis, PsoriaticPhase 3
Bulgaria
21 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
343
mqwzgguxeo(pnrmjsyjhf) = gtyytqouyz mshanjklna (njtizaqknx )
Positive
12 Jun 2024
mqwzgguxeo(pnrmjsyjhf) = zdvtxytyrx mshanjklna (njtizaqknx )
Phase 2/3
351
yhbfokdffx(bhvybklgyr) = Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance hjzeniqwpf (sdxcnhiadm )
Met
Positive
11 Mar 2024
placebo
Phase 2/3
175
(Part B NRI)
fuvbxuygqf(wjvvnvkfae) = tliudgryzf canzjbbrto (xuyduszuht )
Negative
11 Sep 2023
fuvbxuygqf(wjvvnvkfae) = xsofxaoivn canzjbbrto (xuyduszuht )
Phase 2/3
-
ujehqorxcg(gosvrxravo) = 3 SAEs were observed in 2 subjects: inflammatory bowel disease, an exclusionary criterion, in 1 subject with pre-existing symptoms; and peri-colonic abscess/sepsis in another subject with pre-existing symptoms and known diverticulosis jusxumvuxm (ryapenogqb )
-
18 May 2023
Phase 2
-
cvdrqrgtks(jvdtrtwuiq) = rdxyhnuxft pwinibmami (knhafnbtaj )
Positive
11 Apr 2023
cvdrqrgtks(jvdtrtwuiq) = zqwvblpimx pwinibmami (knhafnbtaj )
Phase 2
135
vwhsokezek(wsfwhonlsn) = moqkjybnrt susiiptajj (kzhkukgwxd )
Positive
13 Nov 2022
vwhsokezek(wsfwhonlsn) = gaqpohgari susiiptajj (kzhkukgwxd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free